A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough
Open Access
- 1 January 2022
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (1)
Abstract
Objective: Baclofen is a centrally acting γ-aminobutyric acid type B (GABAB) receptor agonist which reduces gastro-oesophageal reflux and suppresses the cough reflex; however, central nervous system side-effects limit its use. Lesogaberan is a novel peripherally acting GABABagonist, but its effects on refractory chronic cough are unknown.Design: We performed a single-centre, placebo-controlled, double-blind randomised crossover study in patients with chronic cough, refractory to the treatment of underlying conditions. Patients were randomised to treatment with lesogaberan 120 mg modified release twice daily or matched placebo for 2 weeks and then crossed over to the alternative therapy after a 2-week washout. The primary end-point was 24-h cough frequency measured with an acoustic monitoring system. In addition, cough responses to capsaicin were measured, and gastro-oesophageal reflux assessed by 24-h pH/impedance at screening.Results: 22 patients were randomised to receive lesogaberan/placebo or placebo/lesogaberan (female (73%); mean±sdage 63.7±7.2 years; median (interquartile range) cough duration 10.5 (5.8–17.0) years; mean (95% CI) 45 (29–67) reflux events in 24 h; two patients had abnormal oesophageal acid exposure times). Although lesogaberan reduced cough counts by 26% over placebo, this did not reach statistical significance (p=0.12). However, lesogaberan did significantly improve cough responses to capsaicin (p=0.04) and the number of cough bouts (p=0.04) compared with placebo. Lesogaberan was well tolerated in this study.Conclusions: Lesogaberan improved cough hypersensitivity and the number of bouts of coughing, but not coughs per hour. This implies a possible role for peripheral GABABreceptors in refractory chronic cough.Keywords
Funding Information
- Medical Research Council (Joint collaboration with AstraZeneca, MR/K015141/1)
This publication has 39 references indexed in Scilit:
- Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitorsScandinavian Journal of Gastroenterology, 2013
- Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trialGut, 2012
- Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adultsCochrane Database of Systematic Reviews, 2011
- The relationship between gastroesophageal reflux and cough in children with chronic unexplained cough using combined impedance–pH–manometry recordingsPediatric Pulmonology, 2010
- Effect of lesogaberan, a novel GABAB‐receptor agonist, on transient lower oesophageal sphincter relaxations in male subjectsAlimentary Pharmacology & Therapeutics, 2010
- Measuring cough severity: Perspectives from the literature and from patients with chronic coughCough, 2009
- Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48‐h manometric studyNeurogastroenterology & Motility, 2008
- How to quantify coughing: correlations with quality of life in chronic coughEuropean Respiratory Journal, 2008
- ERS guidelines on the assessment of coughEuropean Respiratory Journal, 2007
- Inhibition of Capsaicin‐Induced Cough by the γ‐Aminobutyric Acid Agonist BaclofenThe Journal of Clinical Pharmacology, 1998